Drugs / Coramitug
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07448623 | Mar 2026 → May 2027 expected | amyloidosis | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT03336580 | Apr 2018 → Jul 2020 | hereditary amyloidosis | Prothena Biosciences Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Prothena Biosciences Ltd. | Regulatory Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy prothena.com ↗ |
| 2025-11-11 | Prothena Biosciences Ltd. | Results Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA prothena.com ↗ |
| 2021-04-18 | Prothena Biosciences Ltd. | Results Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 prothena.com ↗
Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting. |
| 2020-12-09 | Prothena Biosciences Ltd. | Results Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis prothena.com ↗
Prothena Corporation plc (NASDAQ:PRTA) today reported positive results from the Phase 1 study of PRX004, the first anti-amyloid immunotherapy designed to deplete amyloid to demonstrate efficacy in ATTR amyloidosis. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coramitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07448623 ↗ |
| Known as | PRX004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03336580 ↗ |
| Action | Deplete | “promotes its removal from the heart” NCT07448623 ↗ |
| Modality | Monoclonal antibody | “Coramitug is a monoclonal antibody” NCT07448623 ↗ |
| Route | Intravenous | “intravenous (IV) PRX004” NCT03336580 ↗ |